INDIA —Alivus Life Sciences Limited has officially set the acquisition process in motion to take over IQGEN-X Pharma Private Limited, following up on a share purchase agreement initially established in August 2026. The enterprise has successfully secured 7,36,096 equity shares, translating to a 65.01% ownership interest of the target's total issued and paid-up capital. With this initial tranche completed, IQGEN-X Pharma has officially transitioned into a subsidiary of the acquiring corporation, while procurement of the remaining equity is slated for finalization in subsequent stages.
Alivus Life Sciences Limited, previously known as Glenmark Life Sciences Limited, is a prominent pharmaceutical entity focused on the development and manufacturing of active pharmaceutical ingredients and intermediate products, operating corporate offices in Mumbai and registered facilities in Solapur. This strategic consolidation enables the parent organization to expand its operational footprint and diversify its portfolio within the pharmaceutical sector, directly accelerating its long-term growth trajectory in specialty therapeutics and generic formulations.
The integration of IQGEN-X Pharma carries notable weight for the broader life sciences sector, particularly impacting market competitors, contract manufacturers, and supply chain partners navigating shifting consolidation trends. Regulatory stakeholders and industry observers are closely monitoring how this majority ownership transition alters market dynamics within pharmaceutical development, contract research, and specialized drug manufacturing segments across the domestic market.
For investors and corporate strategists, this development underscores an ongoing reliance on mergers and acquisitions to capture specialized manufacturing capabilities and enhance product pipelines. Market participants can anticipate heightened valuation scrutiny and strategic portfolio adjustments as the parent organization moves to absorb the remaining minority shares and execute full operational integration.
